Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2011

01-04-2011 | Original Article

Pioglitazone: A Promising Therapeutic Tool in Sodium Taurocholate-Induced Severe Acute Pancreatitis

Authors: Ping Xu, Kai Xu, Jing Wang, Jin-Ping Jiang, Ling-Quan Chen

Published in: Digestive Diseases and Sciences | Issue 4/2011

Login to get access

Abstract

Background

Studies suggest that peroxisome proliferator-activated receptor γ(PPARγ) ligands may represent a therapeutic option in acute pancreatitis, yet most of them have been prophylactic administrated.

Aims

To evaluate the therapeutic effect of pioglitazone in rats with severe acute pancreatitis induced by sodium taurocholate.

Methods

Severe acute pancreatitis (SAP) was induced in male Sprague–Dawley rats by the retrograde injection of 5% sodium taurocholate into the pancreatic duct. After SAP was induced, pioglitazone was injected intraperitoneally and its role on the severity of inflammatory response and pancreatic injury was investigated. Amylase activity, inflammatory cytokines production, pathological changes of pancreas, PPARγ mRNA expression, and the survival rate were examined.

Results

Treatment with pioglitazone decreased the level of amylase activity, proinflammatory factors IL-6 and TNF-α, ameliorated pancreatic histological score, and upregulated the expression of PPARγ mRNA. The survival rate in the early stage of severe acute pancreatitis was also improved.

Conclusions

Pioglitazone can be used as a therapeutic drug and relieve the damages caused by SAP, which suggests PPARγ ligand-pioglitazone offers a potent approach for the treatment of severe acute pancreatitis.
Literature
1.
Chiang DT, Anozie A, Fleming WR, et al. Comparative study on acute pancreatitis management. ANZ J Surg. 2004;74(4):218–221.PubMedCrossRef
2.
Vamecq J, Latruffe N. Medical significance of peroxisome proliferators-activated receptors. Lancet. 1999;354(9173):141–148.PubMedCrossRef
3.
Rahimian R, Masih-Khan E, Lo M, et al. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem. 2001;224(1–2):29–37.PubMedCrossRef
4.
Yin R, Dong YG, Li HL. PPAR gamma phosphorylation mediated by JNK MAPK: a potential role in macrophage-derived foam cell formation. Acta Pharmacol Sin. 2006;27(9):1146–1152.PubMedCrossRef
5.
Wang AC, Dai X, Luu B, et al. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol. 2001;24(6):688–693.PubMed
6.
Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology. 2003;124(5):1315–1324.PubMedCrossRef
7.
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86.PubMedCrossRef
8.
Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82.PubMedCrossRef
9.
Zingarelli B, Sheehan M, Hake PW, et al. Peroxisome proliferator activated receptor-gamma ligands, 15-deoxy-Delta(12, 14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol. 2003;171(12):6827–6837.PubMed
10.
Enomoto N, Takei Y, Hirose M, et al. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther. 2003;306(3):846–854.PubMedCrossRef
11.
Konturek PC, Dembinski A, Warzecha Z, et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulean-induced pancreatitis. World J Gastroenterol. 2005;11(40):6322–6329.PubMed
12.
Hughes CB, Grewal HP, Gaber LW, et al. Anti-TNF alpha therapy improves survival and ameliorates the pathophysiologic saquelae in acute pancreatitis in the rat. Am J Surg. 1996;171(2):274–280.PubMedCrossRef
13.
Schmidt J, Rattner DW, Lewandrowski K, et al. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215(1):44–56.PubMedCrossRef
14.
Xu P, Zhou XJ, Chen LQ, et al. Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis. World J Gastroenterol. 2007;13(13):1983–1988.PubMed
15.
Folch-Puy E, Granell S, Iovanna JL, et al. Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats. World J Gastroenterol. 2006;12(40):6458–6463.PubMed
16.
Hashimoto K, Ethridge RT, Saito H, et al. The PPARgamma ligand, 15d-PGJ2, attenuates the severity of cerulein-induced acute pancreatitis. Pancreas. 2003;27(1):58–66.PubMedCrossRef
17.
Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med. 2004;30(5):951–956.PubMedCrossRef
18.
Chen C, Xu S, Wang WX, et al. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res. 2009;40(2):79–88.PubMedCrossRef
19.
De Beaux AC, Fearon KC. Circulating endotoxin, tumor necrosis factor-alpha, and their natural antagonists in the pathophysiology of acute pancreatitis. Scand J Gastroenterol. 1996;31(219):43–46.CrossRef
20.
De Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg. 1996;83(3):349–353.PubMedCrossRef
21.
Denham W, Yang J, Fink G, et al. Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pancreatitis. Gastroenterology. 1997;113(5):1741–1746.PubMedCrossRef
22.
Rongione AJ, Kusske AM, Kwan K, et al. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology. 1997;112(3):960–967.PubMedCrossRef
23.
Laveda R, Martinez J, Munoz C, et al. Different profile of cytokine synthesis according to the severity of acute pancreatitis. World J Gastroenterol. 2005;11(34):5309–5313.PubMed
24.
Van Laethem JL, Eskinazi R, Louis H, et al. Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice. Gut. 1998;43(3):408–413.PubMedCrossRef
25.
Giri S, Rattan R, Singh AK, et al. The 15-deoxy-delta 12, 14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol. 2004;173(8):5196–5208.PubMed
26.
Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20(13):4699–4707.PubMedCrossRef
27.
Feingold K, Kim MS, Shigenaga J, et al. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab. 2004;286(2):E201–E207.PubMedCrossRef
28.
Hill MR, Young MD, McCurdy CM, et al. Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology. 1997;138(7):3073–3076.PubMedCrossRef
29.
Tanaka T, Itoh H, Doi K, et al. Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia. 1999;42(6):702–710.PubMedCrossRef
30.
Rollins MD, Sudarshan S, Firpo MA, et al. Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis. J Gastrointest Surg. 2006;10(8):1120–1130.PubMedCrossRef
Metadata
Title
Pioglitazone: A Promising Therapeutic Tool in Sodium Taurocholate-Induced Severe Acute Pancreatitis
Authors
Ping Xu
Kai Xu
Jing Wang
Jin-Ping Jiang
Ling-Quan Chen
Publication date
01-04-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1393-0

Other articles of this Issue 4/2011

Digestive Diseases and Sciences 4/2011 Go to the issue

Original Article

HCV-Related Proteins Activate Kupffer Cells Isolated from Human Liver Tissues

Review

Drug-Induced Autoimmune-Like Hepatitis

Original Article

Endoscopic Diagnosis of Open-Type Atrophic Gastritis Is Related to the Histological Diagnosis of Intestinal Metaplasia and Cdx2 Expression

Original Article

Reflux Parameters as Modified by Laparoscopic Fundoplication in 40 Patients with Heartburn/Regurgitation Persisting Despite PPI Therapy: A Study Using Impedance-pH Monitoring

Review

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

Original Article

5-Aminosalicylic Acid (5-ASA) Can Reduce Levels of Oxidative DNA Damage in Cells of Colonic Mucosa With and Without Fecal Stream
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits